Population-based inference of aminoglycoside resistance mechanisms in Escherichia coli by Mancini, Stefano et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2019
Population-based inference of aminoglycoside resistance mechanisms in
Escherichia coli
Mancini, Stefano ; Marchesi, Martina ; Imkamp, Frank ; Wagner, Karoline ; Keller, Peter M ; Quiblier,
Chantal ; Bodendoerfer, Elias ; Courvalin, Patrice ; Böttger, Erik C
Abstract: BACKGROUND Interpretative reading of antimicrobial susceptibility test (AST) results al-
lows inferring biochemical resistance mechanisms from resistance phenotypes. For aminoglycosides, how-
ever, correlations between resistance pathways inferred on the basis of the European Committee on
Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoints and expert rules versus genotypes
are generally poor. This study aimed at developing and validating a decision tree based on resistance
phenotypes determined by disc diffusion and based on epidemiological cut-offs (ECOFFs) to infer the cor-
responding resistance mechanisms in Escherichia coli. METHODS Phenotypic antibiotic susceptibility of
thirty wild-type and 458 aminoglycoside-resistant E. coli clinical isolates was determined by disc diffusion
and the genomes were sequenced. Based on well-defined cut-offs, we developed a phenotype-based algo-
rithm (Aminoglycoside Resistance Mechanism Inference Algorithm - ARMIA) to infer the biochemical
mechanisms responsible for the corresponding aminoglycoside resistance phenotypes. The mechanisms
inferred from susceptibility to kanamycin, tobramycin and gentamicin were analysed using ARMIA- or
EUCAST-based AST interpretation and validated by whole genome sequencing (WGS) of the host bac-
teria. FINDINGS ARMIA-based inference of resistance mechanisms and WGS data were congruent in
441/458 isolates (96·3%). In contrast, there was a poor correlation between resistance mechanisms
inferred using EUCAST CBPs/expert rules and WGS data (418/488, 85·6%). Based on the assump-
tion that resistance mechanisms can result in therapeutic failure, EUCAST produced 63 (12·9%) very
major errors (vME), compared to only 2 (0·4%) vME with ARMIA. When used for detection and iden-
tification of resistance mechanisms, ARMIA resolved >95% vMEs generated by EUCAST-based AST
interpretation. INTERPRETATION This study demonstrates that ECOFF-based analysis of AST data
of only four aminoglycosides provides accurate information on the resistance mechanisms in E. coli. Since
aminoglycoside resistance mechanisms, despite having in certain cases a minimal effect on the minimal
inhibitory concentration, may compromise the bactericidal activity of aminoglycosides, prompt detection
of resistance mechanisms is crucial for therapy. Using ARMIA as an interpretative rule set for editing
AST results allows for better predictions of in vivo activity of this drug class.
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Commentary
Aminoglycoside resistance mechanism inference algorithm: Implication
for underlying resistance mechanisms to aminoglycosides
Abdelaziz Touati ⁎
Laboratoire d'Ecologie Microbienne, Université de Bejaia, 06000, Algeria
The discovery of antibiotics in 1928 and their subsequent large-scale
production are considered to be one of the most important achieve-
ments in the history of medicine [1]. One of themost important discov-
eries after that of β-lactams was streptomycin, the ﬁrst aminoglycoside
discovered. Thehistory of aminoglycosideswas thenmarked by the suc-
cessive introduction of a series of compounds (kanamycin, gentamicin,
and tobramycin) for the treatment of infections due to Gram-negative
bacilli [2].
The recent expansion of extensively drug-resistant (XDR) pathogens
and particularly that of carbapenem-producing Enterobacteriaceae
(CRE) has brought into light aminoglycosides, whichmay retain activity
even in XDR isolates [3]. Speciﬁc indications for aminoglycoside therapy
include amikacin and gentamicin administered intravenously for infec-
tions caused by MDR Gram-negative organisms [4].
Interpretative reading of antimicrobial susceptibility test results al-
lows to analyze the susceptibility pattern and to predict the underlying
resistance mechanisms [5]. Contrary to β-lactams antibiotics, correla-
tions between resistance to aminoglycosides inferred based on the
European Committee on Antimicrobial Susceptibility Testing (EUCAST)
clinical breakpoints and expert rules are generally poor [6]. Therefore,
the need for improvement of detection of aminoglycosides resistance
mechanisms in routine is of great importance.
Recently in EBioMedicine, Mancini and colleagues presented an Ami-
noglycoside Resistance Mechanism Inference Algorithm (ARMIA) for
the inference of resistance mechanisms from inhibition zone diameters
[7]. This algorithm uses ECOFFs for gentamicin, tobramycin and kana-
mycin as well as a working separator cut-off for amikacin. They com-
pared the performance of ARMIA and EUCAST CBPs/expert rules with
that of whole-genome sequencing (WGS) in predicting aminoglycoside
resistance. The results of this study showed that ARMIA-based inference
of resistance mechanisms and WGS data were congruent in 96·3%. In
contrast, there was a poor correlation between resistance mechanisms
inferred using EUCAST CBPs/expert rules and WGS data (85·6%) [7].
When assessing the accuracy of various susceptibility testing
methods as compared to standard reference methods, the terms very
major errors (vME) have been used to describe false susceptible [8].
Thus, in the comparisonmade byMancini and colleagues, they reported
that EUCAST produced 63 (12·9%) vME, compared to only 2 (0·4%) vME
with ARMIA [7].
In vitro susceptibility rates may vary signiﬁcantly, depending on the
aminoglycoside resistance mechanisms, which are frequently co-
transferredalongwithother resistancegenesonmobile genetic elements
[3]. It is reported that aminoglycoside resistance mechanisms, such as
16S rRNA methylase, coexist with other resistance mechanisms
including extended-spectrum β-lactamase, carbapenemase, and
plasmid-mediated quinolone resistance determinants [9]. Thus, it is im-
portant to detect theunderlying aminoglycosides resistancemechanisms
to prevent co-selection of these resistance mechanisms. The ARMIA de-
veloped by Mancini and colleagues would be useful for this purpose to
avoid misidentiﬁcation of the aminoglycoside resistance mechanisms.
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